

Index

- absorption
 - of topically applied copper complexes, 89, 90
 - zinc, 103–21
 - effects of food/food components on, 118–21
 - effects of testing conditions on, 116–17
 - methods of assessment, 113–18
 - physiological factors affecting, 112–13
 - process of, 103–9
- acetate, copper complexes of,
 - anti-inflammatory activity, 74, 75
- acrodermatitis enteropathica, treatment, 107–8
- adjuvant arthritis, anti-inflammatory activity of copper complexes in, 75, 88, 90–1
- albumin
 - antioxidant activity, 14
 - copper complexes with, 10
 - in rheumatoid arthritis, 10
- alcoholic drinks, zinc absorption and the effects of, 120–1
- Alcusal[®], 85–6
- amine oxidases, function, 71
- amino acid(s), zinc transport involving, 106, 107–8
- amino acid-copper complexes, free radical scavenging, 53–4
- cAMP, metallothionein inducibility by, 24, 26
- anaemia, zinc therapy-related, 140–1
- analgesic activities of copper complexes, 76, 77
- ankylosing spondylitis, copper studies in, 3
- anti-inflammatory activities of
 - copper/copper compounds, 52, 54–5, 74–6, 88, 90–1, 98–101
- antioxidant copper proteins, *see* copper proteins
- anti-ulcer activities of copper complexes, 78–81
- apocaeeruloplasmin, copper incorporation into, 25, 26
- apometalloenzymes, copper and zinc donation to, 26
- arthritis
 - adjuvant, anti-inflammatory activity of copper complexes in, 75, 88, 90–1
 - psoriatic, *see* psoriatic arthritis
 - rheumatoid, *see* rheumatoid arthritis
- ascorbic acid levels in rheumatoid arthritis, 13
- aspirin
 - copper complexes and,
 - anti-inflammatory activity of, comparison, 75
 - copper complexes of
 - analgesic activity, 76, 77
 - anti-inflammatory activity, 75
 - anti-ulcer activity, 79, 80
 - toxicity studies, 75, 76
- beverages, zinc absorption and the effects of, 120–1
- bile, copper content, 69
- biodistribution of copper from topically applied copper complexes, 88–90
- bis(2-benzimidazolyl)thioether ligands, 95–101
- bis(glycinato) copper complexes, skin permeation by, 85
- bleomycin, catalytic iron and copper assays employing, 10
- blood cells, peripheral, in inflammatory diseases, zinc concentrations in, 133, *see also specific cell types*
- bone
 - resorption, copper-inhibited, 54
 - zinc incorporation into, zinc bioavailability determined via, 116
- bone marrow
 - progenitor cells, metallothionein expression in, 26
 - zinc in, metabolically active nature of, 26
- bread, dietary, zinc absorption and the effects of, 120
- brush border membrane vesicles, zinc transport studies using, 105
- brush border proteins, zinc transport involving, 106
- caeruloplasmin, 3–4, 13–17, *see also* apocaeeruloplasmin

- copper in, states of, 14
- damage by free radicals, 16–17
- function/action, 2, 13–17, 28, 52, 71
- levels, 3–4
 - normal, 3
 - in various rheumatic disorders, 3–4, 52
- lipid peroxidation and the effects of, 44
- measurement, 16
- calcium, dietary, zinc absorption and the effects of, 118
- carrier-mediated zinc transport, 105–6
- catalytic copper
 - in inflammation, 9–10
 - measurement, 10–11
- catalytic iron, *see* iron
- cereals, dietary, zinc absorption and the effects of, 120
- chloride
 - copper, ligands complexed with, 96, 97
 - anti-inflammatory activity of, 98–101
 - zinc, ligands complexed with, 96
- circulation, zinc transport into, 105–6
- citrate, zinc absorption and the effects of, 107–8
- colon, zinc absorption, 104
- complexes, copper, in treatment of
 - inflammatory conditions, 69–81, 85–91, 93–101, *see also specific complexes*
- copper bracelets, 49–50, 85
- copper complexes in treatment of
 - inflammatory conditions, 69–81, 85–91, 93–101, *see also specific complexes*
- copper proteins with antioxidant role, 7–17, *see also specific proteins*
 - comparisons, 13
- copper salts, *see specific salts*
- copper-thioneine, 72, 73
- corticosteroids, metallothionein
 - inducibility by, 23, 24–5
- Cupralene therapy in rheumatoid arthritis, 50
- L-cysteine supplementation in
 - D-penicillamine therapy, 59
- cytochrome c oxidase, function, 71
- deficiency
 - dietary
 - copper, in inflammatory/arthritis disease, 56–7, 140
 - copper and zinc, lipid peroxidation associated with, 28
 - zinc therapy-related, 140–1
- Dermusal, copper(II) salicylate complexes
 - prepared in, 86
- dibutyryl cAMP, metallothionein gene
 - expression stimulated by, 26
- Dicuprene therapy in rheumatoid arthritis, 50
- diet, *see* food/food components
- dietary deficiency, *see* deficiency
- dietary supplementation, *see also* therapy
 - copper compounds, 1
 - zinc compounds, 2
- dietary zinc, zinc homeostasis and, 109–10, 110–12, 116–17
- diethylamine-(cupro-oxyquinoline)-sulphonate therapy in rheumatoid arthritis, 50
- 3,5-diisopropylsalicylic acid (3,5-dips),
 - copper complexes of
 - analgesic activities, 76
 - superoxide dismutase-mimetic activity, 80
- dimethyl sulphoxide, copper complexes
 - prepared in, topical application, 86, 87, 88, 89
- disease(s) affecting zinc absorption, 113
- disease-modifying drugs, *see* slow-acting drugs
- DNA
 - bleomycin degradation of, copper and iron assays based on, 10
 - synthesis, lymphocytic, inhibitory
 - low-density lipoprotein effects on, 37, 38, 39
- 40, 41
- dopamine- β -hydroxylase, function, 71
- dual isotope faecal collection procedure,
 - zinc absorption determined via, 114
- duodenal mucosa, intracellular proteins in,
 - zinc absorption involving, 109
- duodenum, zinc absorption in, 103–4, 104
- endotoxaemia, metallothionein inducibility
 - in, 24
- endotoxin, metallothionein inducibility by, 24, 24–5
- enzymes, copper-dependent, 71, 72, *see also specific enzymes*
 - function, 71
- epinephrine, metallothionein inducibility
 - by, 24
- excretion
 - of topically applied copper complexes, 89
 - zinc
 - in rheumatoid arthritis, 134

- zinc homeostasis and, 110, 110–12
- extrinsic labels, zinc absorption measured using, 117–18
- factor V, function, 71
- faecal collection procedure, dual isotope, zinc absorption determined via, 114
- faecal monitoring of stable isotopes of zinc, 114–15
- fatty acids, polyunsaturated, free radical attack, 9
- Fenton reaction, 8, 10
 - iron participation in, 8, 28
- ferroxidase activity of caeruloplasmin, 14
 - assay, 16
- fibre, dietary, zinc absorption and the effects of, 120
- folic acid supplements, zinc absorption and the effects of, 118
- food/food components, zinc absorption from, 112–21, *see also* entries under dietary
 - effects of food/food components on, 118–21
 - effects of testing conditions on, 116–17
 - methods of assessment, 113–18
 - physiological factors affecting, 112–13
- free radicals, oxygen-derived
 - damage/injury by, 34, 42, 54, 55
 - of caeruloplasmin 16–17
 - in vitro* models of, 15
 - generation, 8, 34, 42, 52–3, 54
 - oxidation products, 34, 35
 - scavenging, 52–4
 - by caeruloplasmin, 14–15, 28
 - by metallothionein, 28–9
- gall bladder, copper content, 69
- gastric acid secretion, copper complexes and their effects on, 79
- gastrointestinal tract
 - copper complexes in, dissociation/instability, 94
 - zinc absorption, 103–9
- α 2-globulin, 13
- glucagon, metallothionein inducibility by, 24, 25
- glucocorticoids, metallothionein inducibility by, 23, 24–5
- gold therapy in rheumatoid arthritis, effects on zinc status, 134–5
- gout, caeruloplasmin levels in, 4
- granuloma models, copper complexes in
 - anti-inflammatory activity, 75
 - biodistribution, 89–90
 - growth differences, zinc bioavailability determined from, 116
- hair, zinc loss via, 112
- hepatocytes
 - copper metabolism in, 25–6
 - lipid peroxidation in
 - induction, 29
 - reduction, metallothionein-related, 29
 - zinc uptake/exchange in, 25
- hepatolenticular degeneration, *see* Wilson's disease
- histamine
 - activity, copper complexes and their effects on, 79–80
 - copper complexes with, anti-ulcer and anti-secretory properties, 79
- homeostasis, zinc, 109–12
- hormones
 - copper and zinc metabolism regulated by, 21
 - metallothionein inducibility by, 23–4
- hydroperoxides, lipid, iron reacting with, 43
- hydroxyl radical
 - generation and effects, 8
 - iron reacting with, 43
 - scavenging of, by metallothionein, 29
- hypoxanthine as source of free radicals, 15
- ileum, zinc absorption in, 103–4
- imidazolyl group-containing ligands, 95
- immunochemical assay of caeruloplasmin, 16
- immunoglobulin G
 - degradation, copper involvement, 11
 - free radical reactions involving, 45
- indomethacin, copper complexes of, analgesic activity, 76, 77
- infection, acute, metallothionein inducibility in, 24
- inflammatory cells in rheumatoid
 - inflammation, free radical generation by, 4
- interleukin-1, metallothionein expression raised by, 25
- intestinal cell, zinc absorption and the role of, 108–9
- intestine
 - zinc absorption in, 103–9
 - zinc excretion into, 110
- ionic copper content in tissues, 70

- iron
- catalytic
 - in inflammation, 9–10
 - measurement, 10–11
 - dietary, zinc absorption and the effects of, 118
 - lipid peroxidation promoted by, 36, 36–7, 43
 - oxidation, caeruloplasmin-mediated, 14
 - as a pro-oxidant, 7–11, 36
- isotopes of zinc
- radio-, zinc absorption determined using, 114–15
 - stable/non-radioactive, faecal monitoring of, 114–15
- jejunal mucosa, intracellular proteins in, zinc absorption involving, 109
- jejunum, zinc absorption, 103–4
- ligands
- copper-specific, 70, 72, 93–101
 - chemistry, 96–8
 - choice, 95
 - pharmacology, 98–101
 - zinc uptake/absorption-enhancing, 106, 107, 108
- lipid hydroperoxides, iron reacting with, 43
- lipid peroxidation, 33–46
- beneficial effects, 45
 - copper and iron-dependent, 33–46, 55
 - cellular enhancement, 39–42
 - copper and zinc-deficiency associated, 28
 - free radical reactions associated with, 9
 - metallothionein-associated reduction, 29
- lipophilic copper salicylate complexes, *see* salicylic acid, copper complexes of
- lipoprotein, low-density, 33–46
- inhibitory effects, 36–7
 - lipid peroxidation of, 33–46
 - copper or iron-dependent, 33–46
 - inflammation and, 42–5
 - oxidized, effects, 44–5
- lumen, solutes in the, zinc absorption and the effects of, 106–8
- lupus erythematosus, systemic, caeruloplasmin levels in, 4
- lymphocytes
- low-density lipoprotein (iron and copper-modified) effects on, 36–7, 38, 39, 39–42, 44, 45
 - penicillamine-copper complexes and their effects on, 59
- lysyl oxidase, function, 71, *see also* peptidyl lysyl oxidase
- macrophages, metallothionein effects on, 28
- marrow, *see* bone marrow
- mass spectrometry, isotopic analysis of faeces using, 115
- menses, zinc loss via, 112
- metabolism
- copper, 72
 - metallothionein role in, 21–9
 - perturbation in Wilson's disease, 3
 - zinc, 103–21
 - metallothionein role in, 21–9
- metal(s), trace, *see also* minerals
- lipid peroxidation promoted by, 36
 - metabolism, metallothionein and, 25–6
 - toxicity, metallothionein role in withstanding, 28
- metal regulating element (MRE)
- sequences, 22–3
- metallothionein, 21–9
- general characteristics, 21–2
 - inducibility/gene expression, 22–5, 26–8 *passim*, 108
 - by hormones, 23–5
 - by metals, 22–3, 108
- isoforms, 21–2
- role
- in copper and zinc metabolism, 21–9, 108–9
 - in inflammation, 26–9
- milk
- dietary, zinc absorption and the effects of, 119, 120–1
 - human
 - zinc-binding ligands in, 107–8
 - zinc loss via, 112
- minerals, dietary, zinc absorption and the effects of, 118, *see also* metals
- mononuclear cells, peripheral blood
- iron and copper-modified low-density lipoproteins and their effects on, 36–7
 - lipid peroxidation of low-density lipoproteins involving, 36–7, 40–1
- mucosa, intestinal, intracellular proteins in, zinc transport involving, 109
- niflumic acid, copper complexes with
- analgesic activity, 76, 77
 - anti-arthritic activity, 88
- non-steroid anti-inflammatory drugs

- copper complexes of, anti-ulcer activity, 78
 pharmacological activity
 copper involvement in, 55
 in psoriatic arthritis, 136, 137
 NSN ligands, 95–101
- oedema, paw, *see* paw oedema
- oral contraceptives, effects in rheumatoid arthritis, 51–2
- Orgotein, therapeutic value, 53
- osteoarthritis
 caeruloplasmin levels in, 4
 zinc levels in, 134
- oxidation-reduction reactions, metals involved in, 7
- oxygen
 in oxidative reactions, 7–8
 toxicity, 8
- oxygen-derived free radicals, *see* free radicals
- pain, copper complexes relieving, 76, 77
- Palosein, 12
- pancreatic origin, zinc-associating ligands of, 106
- paw oedema, copper complexes in
 anti-inflammatory activity, 75, 86–7, 98–101
 biodistribution, 89
- D-penicillamine, 57–60
 lymphocytic responses to, 44
 pharmacological activity, copper involvement, 55–6, 58
 therapeutic effects, 57–60, 135
 compared with copper complexes, 75
 zinc-abbreviated, 60
 zinc status and the effects of, 134
- D-penicillamine-copper complexes
 anti-ulcer activity, 79
 rheumatoid arthritis treatment using, 57, 58, 59
- peptidyl α -amidating enzymes, function, 71, 81
- peptidyl lysyl oxidase, *see also* lysyl oxidase
 activation, 76
 synthesis, 80
- perchlorate, copper, ligand complexes with, 96, 97, 98
 anti-inflammatory activity, 98–101
- Permalon therapy, 50
- permeation of skin by copper complexes, 85–9
- peroxidation, lipid, *see* lipid peroxidation
- pH, copper complexes and their stability related to, 94
- phenanthroline assay, copper and iron detection by, 10–11
- phenylbutazone, copper complex of, anti-arthritic activity, 88
- phytates, dietary, zinc absorption and the effects of, 120
- phytohaemagglutinin-stimulated lymphocytes, inhibitory low-density lipoproteins and their effects on, 37, 38, 39, 40, 41
- picolinic acid, zinc absorption and the effects of, 107–8
- plant food, zinc absorption and the effects of, 119, 120
- plasma, zinc levels in
 in psoriatic arthritis, 135–6
 in rheumatoid arthritis, 133, 134
- plasma tolerance curves, zinc absorption determined via, 116
- polyunsaturated fatty acids, free radical attack of, 9
- pregnancy in rheumatoid arthritis, effects, 51
- pro-oxidants, copper and iron as, 7–11
- prostaglandins, zinc absorption and the effects of, 106–7
- proteins
 copper, antioxidant, *see* copper proteins
 dietary, zinc absorption and the effects of, 119–20
 intracellular, zinc absorption and the role of, 108–9
 transport-, 2
- psoriatic arthritis, 135–41
 zinc status in, 135–6
 zinc therapy in, 136–41
- pyridoxine HCl, zinc absorption and the effects of, 118
- radioisotopes, zinc, zinc absorption determined using, 114–15
- redox reactions, metals involved in, 7
- rheumatic disorders, caeruloplasmin levels in various, 3–4
- rheumatoid arthritis, 133–5
 caeruloplasmin levels in, 4
 copper levels in, 10
 serum, 9
 copper therapy, 50–60
 lipid peroxidation in, 33, 34
 trace metal levels in, 2
 zinc status, 133–5

- zinc therapy, 2–3, 135, 140
- mRNA expression, metallothionein, induction, 23–5 *passim*
- salicylic acid/salicylate, pharmacological activity of, copper involvement in, 55
- salicylic acid/salicylate, copper complexes of, 85–91
- analgesic activity, 76, 77
 - anti-ulcer activity, 79–80
 - topically applied/lipolytic, 85–91
 - biodistribution, 88–90
 - development, 85–6
 - efficacy, 86–8
 - mode of action, 90–1
 - semen, zinc loss via, 112
 - side-effects of zinc preparations, 140–1, *see also* toxicity
 - slope-ratio assays, zinc bioavailability determined via, 116
 - slow-acting/disease-modifying
 - anti-inflammatory drugs, pharmacological activity, 59
 - copper involvement, 55–6
 - sodium-meta-(allylcuprothiocarbamido)-benzoate therapy in rheumatoid arthritis, 50
 - solutes in the lumen, effects on zinc absorption, 106–8
 - soy protein, zinc absorption and the effects of, 119
 - spondylitis, ankylosing, copper studies in, 3
 - stress, metallothionein inducibility by, 23
 - sulphate, zinc, *see* zinc sulphate therapy
 - superoxide (O_2^-)
 - dismutation, 11–12
 - inhibitory low-density lipoprotein generation involving, 37–9
 - generation during inflammation, 8, 42, 52–3
 - effects, 42, 55
 - scavenging, 52–4
 - by caeruloplasmin, 14–15
 - by metallothionein, 28–9
 - by superoxide dismutase, 11, 53
 - superoxide dismutase, 11–13, 71
 - activation, 76
 - caeruloplasmin activity compared with, 15
 - extracellular, 12–13
 - in inflammation, 11
 - efficacy, 16
 - inhibitory low-density lipoprotein and the effects of, 38, 39
 - lipid peroxidation and the effects of, 43
 - protection by, from free radical damage, 15, 53
 - therapeutic value, 53
 - zinc therapy and its effects on, 141
 - sweat, zinc loss via, 112
 - synovial fluid
 - caeruloplasmin in, 16
 - forms, 16
 - in rheumatoid disease
 - copper levels in, 10
 - lipid peroxidation in, 33, 34, 35, 42–3
 - lipoproteins in, 35, 42
 - superoxide dismutase levels in, extracellular, 13
 - superoxide dismutase-mimetic activity of anti-ulcer copper complexes, 80
 - systemic lupus erythematosus, caeruloplasmin levels in, 4
 - T-lymphocytes, copper-penicillamine complexes and their effects on, 59
 - therapy
 - copper, 1, 49–102
 - zinc, 2–3, 133–41
 - thiobarbituric acid-reactive substances (TBARS) in rheumatoid synovial fluid, 34, 35, 36, 37, 41
 - thioetheral group-containing ligands, 95
 - thioetheral sulphur donor-containing ligands, 95
 - thiols, copper actions mediated by, 58, *see also* specific thiols
 - thioneine, copper-, 72, 73
 - tissue
 - copper content, 69–70
 - damage, by free radicals, *see* free radicals
 - topically applied copper complexes, efficacy and biodistribution, 85–91
 - toxicity, *see also* side-effects
 - of copper complexes, 75–6
 - of zinc preparations, 140
 - trace metals, *see* metals, trace
 - transcuprein, 72, 73
 - transport, zinc, 103–21
 - transport proteins, 2
 - treatment, *see* therapy
 - tridentate ligands, 95
 - tryptophan, copper complexes with, anti-ulcer activity, 80
 - tyrosinase, function, 71

INDEX

- ulcer, copper complexes protecting against, 78–81
- urinary output/excretion of zinc, 111
 - in rheumatoid arthritis, 134
- vascular system, zinc transport into, 105–6
- vitamins
 - dietary, zinc absorption and the effects of, 118–19
 - in rheumatoid arthritis, 13
- whole-body retention of zinc, zinc absorption determined from, 114
- Wilson's disease (hepatolenticular degeneration)
 - copper metabolic perturbation in, 3
 - zinc therapy in, 140
- xanthine oxidase activity, free radicals associated with, 15
- zinc sulphate therapy
 - in psoriatic arthritis, 136–40
 - in rheumatoid arthritis, 2–3, 135